Targeting ADAM17 with siRNA reverted the malignant phenotype in T4-2 breast cancer cell line [11] and strongly inhibited the growth of two independent human renal carcinoma cell lines in immunocompromised mice [12]. This evidence concerns the gene ADAM17 and breast cancer.